Alicon's lead product is Caligel, which are calibrated resorbable gelform particles commonly used as an embolic agent in China for treating liver cancer. Alicon has an integrated R&D, manufacturing and commercialization infrastructure, with over 1,000 major hospitals in China using the Alicon solution to treat 200,000 patients annually.
Transaction and Financial Details
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Varian is financing the $185 million purchase price using cash and proceeds from borrowings.
Endocare and Alicon generated combined revenue of $30 million in calendar 2018. Varian expects the aggregate of these transactions to have an immaterial impact on fiscal year 2019 financial results, and the combined interventional oncology platform to be accretive to GAAP and Non-GAAP earnings per share in fiscal 2020.
About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.
Back to HCB News
